Calliditas Therapeutics
Peter Einarsson has a strong background in accounting and advisory roles. Peter began their career at EY in 2000 as an Authorized Auditor, where they worked until 2013. After that, they joined Matrisen as a Senior Advisor from 2013 to 2016. Following that, they worked at Accountor Sverige as a Senior Advisor from 2016 to 2022. Presently, they are employed as the Director Group Accounting at Calliditas Therapeutics since 2022.
Peter Einarsson attended Örebro University from 1996 to 1999, where they earned a Ekonomie kandidatexamen (ek.kand.) degree in Redovisning.
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.